Heron Therapeutics announced the appointment of William Forbes, Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard, Heron’s Executive Vice President, Drug Development, has resigned from her position. Dr. Forbes joins Heron’s management team and will be responsible for leading clinical and product development for Heron’s acute care and oncology care franchises.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HRTX:
- Biotech Alert: Searches spiking for these stocks today
- Disastrous Earnings Report Takes Down Heron Therapeutics
- Heron Therapeutics Announces Financial Results for the Three Months Ended March 31, 2023 and Highlights Recent Corporate Updates
- HRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- GRI Bio announces board of director appointments